Delivery Order SPE2DR25D3103-SPE2DR26F9G25
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $7,112.21 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors, with an ultimate completion date of September 9, 2025. This competitively awarded, firm fixed price order represents a single delivery transaction under AmerisourceBergen's larger contract vehicle with DLA. The contract was executed on September 8, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a $61,467.35 delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on November 3, 2025, with a completion date of November 4, 2025. This non-competitive, firm fixed-price delivery order represents a single-source procurement under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The company, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical...
- The Defense Logistics Agency awarded a $16,998.05 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 14, 2025, with completion scheduled for July 15, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery is scheduled to occur at AmerisourceBergen's...
- The Defense Logistics Agency awarded a $82,694.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on November 3, 2025, with an ultimate completion date of November 4, 2025. This is a non-set-aside competitively awarded contract for pharmaceutical supply to support federal medical procurement needs. The award was executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and serves as a child delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $4,399.71 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 8, 2025, with an ultimate completion date of August 11, 2025. This non-competitive delivery order utilizes firm fixed price terms and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $11,111.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Dupixent 200 mg/1.14 ml pen auto-injectors, with an ultimate completion date of November 18, 2025. This non-competitive, non-set-aside award was issued on November 17, 2025, with performance taking place at AmerisourceBergen's Corporate Office headquarters in Conshohocken, Pennsylvania. The delivery order represents a child contract action, likely executed under...
- The Defense Logistics Agency awarded a $11,264.48 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 200 mg/1.14 ml pen injectors on November 3, 2025, with an ultimate completion date of November 4, 2025. The contract, which carries no set-aside designation, represents a competitive award to the prime contractor for pharmaceutical delivery to the place of performance in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $3,418.92 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectors, with an ultimate completion date of June 20, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical will be delivered to the...
- The Defense Logistics Agency awarded a $56,299.22 delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors. The contract, awarded on October 29, 2025, with an ultimate completion date of October 30, 2025, represents a firm fixed-price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor for this pharmaceutical supply requirement, which will be fulfilled at...
- The Defense Logistics Agency awarded a delivery order valued at $12,257.90 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on November 4, 2025, with an ultimate completion date of November 5, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating it was awarded through open competition. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents...
- SPE2DR25D3103Indefinite Delivery Contract
- SPE2DR25D3103-SPE2DR26F9G25Delivery Order
The Defense Logistics Agency awarded a $11,491.12 firm fixed price delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors. The award was made on November 18, 2025, with an ultimate completion date of November 19, 2025, and represents a non-competitive, non-set-aside procurement. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp serves as a critical pharmaceutical supplier to the Defense Logistics Agency's Medical Supply Chain, providing a comprehensive range of brand-name and generic medications, vaccines, and specialized medical supplies to support military healthcare programs worldwide. The company's DLA IDC vehicle enables delivery of pharmaceutical products across multiple therapeutic domains to support the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. Dupixent is a biologic treatment commonly used for moderate-to-severe eczema, asthma, and other allergic conditions, and this procurement ensures adequate pharmaceutical inventory for military medical facilities and personnel.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.5k | 11/18/25 |